Mean changes in the modified total Sharp score from baseline to month 6 were significantly smaller in the tofacitinib groups than in the methotrexate group , but changes were modest in all three groups ( 0.2 points in the 5-mg tofacitinib group and < 0.1 point in the 10-mg tofacitinib group , as compared with 0.8 points in the methotrexate group [ P < 0.001 for both comparisons ] ) .